COMMUNIQUÉS West-GlobeNewswire

Nanox to Report Third Quarter and Financial Results on November 21, 2024
11/11/2024
PETACH TIKVA, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial [...]
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
11/11/2024
FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for [...]
Invizyne Technologies Announces Pricing of $15 Million Initial Public Offering
11/11/2024
Shares to Begin Trading on NASDAQ on November 12, 2024, Under the Ticker Symbol “IZTC” Monrovia, CA, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of cell-free, enzyme-based [...]
Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for GRANITE Study and Provides Business Update
11/11/2024
-- 27% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.73 [90% CI, 0.44, 1.21]) -- -- 50% relative risk reduction of progression or death with GRANITE vs. control [...]
Stereotaxis Reports 2024 Third Quarter Financial Results
11/11/2024
ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third [...]
Assertio Reports Third Quarter 2024 Financial Results
11/11/2024
Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings [...]
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
11/11/2024
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, [...]
Celldex Therapeutics to Present at Upcoming Investor Conferences
11/11/2024
HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: Guggenheim Healthcare Innovation [...]
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
11/11/2024
NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers [...]
Norton West Louisville Hospital opens
11/11/2024
$90 million facility aims to improve access to care for residents in historically underserved area of the city LOUISVILLE, Ky., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Norton West Louisville Hospital opened its doors to [...]
UPDATE - New Paper: Leading Health Economists Explain How to Fix the Faulty & Outdated Models Used to Calculate the Value of Medicines
11/11/2024
Access to Life-Saving Drugs can be Delayed or Denied when Regulators and Health Plans Rely on Outdated Cost-Effectiveness Analysis (CEA) Methodology WASHINGTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- As policymakers [...]
French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials for its first-in-class compound for Insulin Resistance
11/11/2024
Global Investments Pave Way for Breakthrough Treatment for Type 2 Diabetes STRASBOURG, France, Nov. 11, 2024 (GLOBE NEWSWIRE) -- AdipoPharma , a biotech company headquartered in France with offices in the US and Belgium [...]
Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions
11/11/2024
Allschwil, Switzerland – November 11, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, the first-and-only dual endothelin receptor antagonist (ERA) for the treatment of systemic hypertension, [...]
QC Kinetix National Medical Director Dr. Mitchell Sheinkop is the Keynote Speaker at the International Conference on Stem Cells and Regenerative Medicine
11/11/2024
Dr. Sheinkop will advise physicians involved in Regenerative Medicine worldwide on “Translating the Potential of OrthoBiologics Treatment into Clinical Practice” Dr. Mitchell Sheinkop CHARLOTTE, N.C., Nov. 11, 2024 ( [...]
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
11/11/2024
Company announcement – No. 50 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, [...]
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2024
11/11/2024
MINNEAPOLIS, MN, US, Nov. 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for [...]
New Paper: Leading Health Economists Explain How to Fix the Faulty & Outdated Models Used to Calculate the Value of Medicines
11/11/2024
Access to Life-Saving Drugs can be Delayed or Denied when Regulators and Health Plans Rely on Outdated Cost-Effectiveness Analysis (CEA) Methodology WASHINGTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- As policymakers [...]
ProPhase Labs Inc. to Present Third Quarter 2024 Financial Results on November 13, 2024
11/11/2024
GARDEN CITY, NY, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and diagnostics company, today announced that they will be [...]
Johnson & Johnson dépose des demandes d’autorisation aux États-Unis et dans l’Union européenne du DARZALEX FASPRO®/DARZALEX® (daratumumab) en tant que monothérapie sous-cutanée destinée au traitement du myélome multiple indolent à haut risq
11/11/2024
En cas d’obtention de l’autorisation, le daratumumab deviendra la première option thérapeutique pour les patients atteints d’un myélome multiple indolent et présentant un risque élevé de développer un myélome multiple, [...]

Pages